- Home
- ABBV
ABBV
AbbVie Inc.
as 04-25-2025 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 312.8B | IPO Year: | N/A |
| Target Price: | $211.81 | AVG Volume (30 days): | 9.7M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.34 | EPS Growth: | -30.38 |
| 52 Week Low/High: | $153.58 - $218.66 | Next Earning Date: | 04-25-2025 |
| Revenue: | $57,367,000,000 | Revenue Growth: | 5.45% |
| Revenue Growth (this year): | 7.79% | Revenue Growth (next year): | 7.92% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stewart Jeffrey Ryan | ABBV | EVP, CHIEF COMMERCIAL OFFICER | Mar 31 '25 | Sell | $210.02 | 58,832 | $12,359,504.28 | 53,234 | |
| Reents Scott T | ABBV | EVP, CHIEF FINANCIAL OFFICER | Mar 14 '25 | Sell | $212.34 | 17,644 | $3,746,526.96 | 11,577 | |
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 28 '25 | Sell | $207.30 | 27,900 | $5,822,401.63 | 4,619 | |
| GONZALEZ RICHARD A | ABBV | Director | Feb 28 '25 | Sell | $207.82 | 98,628 | $20,263,019.64 | 388,929 | |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Feb 28 '25 | Sell | $210.59 | 21,250 | $4,472,038.78 | 21,703 | |
| RICHMOND TIMOTHY J. | ABBV | EVP, CHIEF HR OFFICER | Feb 26 '25 | Sell | $202.86 | 29,917 | $6,070,036.16 | 21,703 | |
| Buckbee Kevin K | ABBV | SVP, CONTROLLER | Feb 26 '25 | Sell | $203.41 | 18,944 | $3,853,372.20 | 11,496 | |
| Siatis Perry C | ABBV | EVP, GC AND SECRETARY | Feb 20 '25 | Sell | $197.76 | 5,778 | $1,143,452.88 | 4,619 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT Newswires
a day ago
Sector Update: Health Care
Investor's Business Daily
a day ago
AbbVie Jumps After Hiking Its Outlook On The Back Of Strong Immunology Sales
Barrons.com
a day ago
AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet.
Insider Monkey
a day ago
AbbVie Inc. (ABBV): One of the Growing Dividend Stocks with Low PE Ratios
StockStory
a day ago
AbbVie (NYSE:ABBV) Reports Bullish Q1
MT Newswires
a day ago
AbbVie Q1 Adjusted Earnings, Revenue Increase; 2025 Adjusted EPS Outlook Lifted
Associated Press Finance
a day ago
AbbVie: Q1 Earnings Snapshot
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.